About this Research Topic
In recent decades, the field of clinical research has made significant progress in understanding and treating Systemic Lupus Erythematosus (SLE) and Sjögren’s disease. These autoimmune disorders have been extensively studied as separate entities, yet there remains a substantial gap in our understanding of their co-occurrence. While individual disease mechanisms, organ involvement, and treatment options have been explored, the intersection of SLE and Sjögren’s disease presents unique challenges and unanswered questions. Notably, autoantibodies such as anti-SSA (Ro) and anti-SSB (La), commonly associated with Sjögren’s, have been detected in SLE patients, though their clinical significance remains unclear. Similarly, the presence of anti-double-stranded DNA antibodies in Sjögren’s patients often lacks clinical relevance. This research topic seeks to address these gaps by focusing on the mutual influence of SLE and Sjögren’s, emphasizing recent advancements, ongoing challenges, and future directions in this area.
This Research Topic aims to elucidate the complex relationship between SLE and Sjögren’s disease. Specifically, it seeks to determine whether the concomitant occurrence of these diseases alters specific disease characteristics, and how the presence of Sjögren’s-associated autoantibodies or an SLE diagnosis impacts patient outcomes. Additionally, the research will explore how anti-dsDNA antibodies influence Sjögren’s disease features. By investigating potential biomarkers and molecular pathways, the goal is to enhance our understanding of the interplay between these diseases and its implications for disease manifestations and treatment strategies.
To gather further insights into the mutual influence of SLE and Sjögren’s disease, we welcome articles addressing, but not limited to, the following themes:
- Comparative analysis of disease characteristics in patients with both SLE and Sjögren’s.
- The role of Sjögren’s-associated autoantibodies in modifying SLE outcomes.
- Impact of anti-dsDNA antibodies on Sjögren’s disease features.
- Identification of potential biomarkers for the co-occurrence of SLE and Sjögren’s.
- Exploration of molecular pathways involved in the interplay between SLE and Sjögren’s.
- Clinical implications of the co-occurrence of SLE and Sjögren’s on treatment strategies.
This Research Topic aims to elucidate the complex relationship between SLE and Sjögren’s disease. Specifically, it seeks to determine whether the concomitant occurrence of these diseases alters specific disease characteristics, and how the presence of Sjögren’s-associated autoantibodies or an SLE diagnosis impacts patient outcomes. Additionally, the research will explore how anti-dsDNA antibodies influence Sjögren’s disease features. By investigating potential biomarkers and molecular pathways, the goal is to enhance our understanding of the interplay between these diseases and its implications for disease manifestations and treatment strategies.
To gather further insights into the mutual influence of SLE and Sjögren’s disease, we welcome articles addressing, but not limited to, the following themes:
- Comparative analysis of disease characteristics in patients with both SLE and Sjögren’s.
- The role of Sjögren’s-associated autoantibodies in modifying SLE outcomes.
- Impact of anti-dsDNA antibodies on Sjögren’s disease features.
- Identification of potential biomarkers for the co-occurrence of SLE and Sjögren’s.
- Exploration of molecular pathways involved in the interplay between SLE and Sjögren’s.
- Clinical implications of the co-occurrence of SLE and Sjögren’s on treatment strategies.
Keywords: SLE, Sjogren, Sjogren's disease, secondary Sjogren, outcomes, Systemic Lupus Erythematosus, concomitant diseases, polyautoimmunity
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
